Arcturus Therapeutics Holdings Gestione
Criteri Gestione verificati 4/4
Arcturus Therapeutics Holdings Il CEO è Joe Payne, nominato in Mar2013, e ha un mandato di 13.5 anni. la retribuzione annua totale è $ 1.69M, composta da 44.4% di stipendio e 55.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.21% delle azioni della società, per un valore di $ 23.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 7.7 anni.
Informazioni chiave
Joe Payne
Amministratore delegato
US$1.7m
Compenso totale
| Percentuale dello stipendio del CEO | 44.35% |
| Mandato del CEO | 13.5yrs |
| Proprietà del CEO | 5.2% |
| Durata media del management | 3.2yrs |
| Durata media del Consiglio di amministrazione | 7.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Nuova narrativa • Sep 08
Rare Disease Pipeline And sa mRNA Vaccine Platform Will Reshape Long Term Outlook
Catalysts About Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings develops mRNA based therapeutics and vaccines focused on rare diseases and infectious diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jul 20
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold
Summary Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 30
ARCT: Index Removals And New CFO Appointment Will Support Future Upside
Analysts have cut their 12 month price target for Arcturus Therapeutics Holdings to $37.46 from $54.97, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What’s in the News for Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings was removed from the Russell 3000E Growth Benchmark index, according to index constituent changes.
Aggiornamento narrativa • Jun 16
ARCT: Future Returns Will Rely On Rare Disease Pipeline Execution And CFO Transition
Analysts have modestly raised their price target on Arcturus Therapeutics Holdings stock, pointing to a slightly lower discount rate and small adjustments to revenue, profit margin, and future P/E assumptions as support for the new $8.00 level. What’s in the News for Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings appointed Dennis Mulroy as Chief Financial Officer, effective May 1, 2026, with the Board approving the appointment on April 15, 2026.Aggiornamento narrativa • Jun 02
ARCT: Future Returns Will Depend On Rare Disease Pipeline Execution Reset
Analysts have trimmed Arcturus Therapeutics Holdings' consensus price targets, with cuts such as $66 to $21 and $72 to $25, alongside a modest move from $7 to $8. This reflects more conservative models after mixed execution and the removal of LUNAR-COVID economics, even as updated research still points to potential upside from ARCT-032 and ARCT-810 progress.
Nuova narrativa • May 22
Arcturus Therapeutics: Strategic opportunities beyond CSL
CSL has turned a promising collaboration into a significant liability. The pivot away from CSL towards new collaboration partners could multiply the market capitalization of Arcturus Therapeutics.Aggiornamento narrativa • May 17
ARCT: Future Returns Will Hinge On Rare Disease Program Execution
Analysts updated their price targets on Arcturus Therapeutics to a tighter range around $8, reflecting revised models that trim COVID-related expectations while emphasizing ongoing progress in cystic fibrosis and ornithine transcarbamylase deficiency programs, along with mixed but generally constructive views on the stock's risk and reward profile. Analyst Commentary Street research around Arcturus Therapeutics has tightened around more conservative assumptions, with several bearish analysts trimming price targets and highlighting execution risk around key programs.Articolo di analisi • May 12
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) recently reported its first-quarter numbers...Aggiornamento narrativa • May 02
ARCT: CF And OTCD Pipeline Progress Will Support Future Share Price Upside
Analysts have adjusted their price targets on Arcturus Therapeutics to a lower range, now spanning roughly $8 to $25, as they recalibrate models following Q4 updates, remove the LUNAR COVID profit share, and balance ongoing execution questions with continued confidence in the ARCT-032 and ARCT-810 programs. Analyst Commentary Recent Street research shows that while price targets on Arcturus Therapeutics have moved to a lower band, some bullish analysts still see room for upside based on the company’s clinical pipeline and execution on key programs.Aggiornamento narrativa • Apr 18
ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Analysts have modestly adjusted the average price target on Arcturus Therapeutics Holdings, reflecting updated assumptions around program execution, mixed Q4 commentary, and the removal of certain COVID-related profit share contributions, while still citing ongoing interest in cystic fibrosis and ornithine transcarbamylase deficiency programs. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings reflects a mix of cautious and constructive views, with several firms recalibrating their models after the latest Q4 update.Aggiornamento narrativa • Apr 02
ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress
Analysts have raised the fair value estimate for Arcturus Therapeutics Holdings to $8.00 from $7.00, based on updated models that incorporate more conservative revenue expectations, higher projected profit margins and recent Street research that reduces longer term targets while still highlighting clinical progress in key programs. Analyst Commentary Recent Street research around Arcturus Therapeutics shows a mix of cautious and constructive views, with several firms revising their models after the latest quarterly update and pipeline commentary.Aggiornamento narrativa • Mar 19
ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside
Analysts have reset their models on Arcturus Therapeutics Holdings, cutting the implied fair value estimate from about $72 to about $55 as they factor in more conservative profit margins, a slightly higher discount rate, removal of COVID-related upside, and a sharper focus on the cystic fibrosis and ornithine transcarbamylase deficiency pipelines. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings shows a wide range of fair value views, but several bullish analysts continue to see upside potential even after cutting price targets and removing COVID-related assumptions from their models.Aggiornamento narrativa • Mar 04
ARCT: Elevated Future P/E Assumptions Will Pressure Execution Risk Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, reflecting updated assumptions around discount rates, revenue growth, margins and future P/E, supported by a recent bullish initiation from Roth Capital and similar research commentary from other firms. Analyst Commentary While some research has turned more constructive, you are also seeing a thread of caution in recent commentary on Arcturus Therapeutics Holdings.Aggiornamento narrativa • Feb 18
ARCT: Bullish Coverage And Execution Risks Will Shape Fairly Valued Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, up from $7, citing a new bullish initiation that highlights the company’s fair value, long term revenue and margin assumptions, and expected future P/E as key supports for the revised view. Analyst Commentary While the new initiation frames US$7.00 as a reasonable reference point, bearish analysts continue to flag risks that could pressure the stock if execution does not line up with the assumptions behind that fair value, especially around long term revenue, margins, and the P/E that is being used in models.Aggiornamento narrativa • Feb 02
ARCT: Bullish Coverage And Higher Future P/E Will Frame Execution Risks
Analysts have lifted their price target on Arcturus Therapeutics Holdings, pointing to a fair value view of US$7.00 per share. This is supported by a slightly lower discount rate, a more conservative revenue growth outlook and a higher assumed future P/E multiple, with recent bullish Street research helping to justify the updated stance.Aggiornamento narrativa • Jan 19
ARCT: Neutral Downgrade And Fair Value View Will Frame Execution Risks
Analysts reduced their fair value estimate for Arcturus Therapeutics Holdings from US$9.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E following the recent downgrade to Neutral by Street research. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the recent downgrade to Neutral framing the stock as more of a wait and see situation rather than a clear opportunity at current levels.Aggiornamento narrativa • Jan 05
ARCT: Neutral Downgrade Will Set Up Potential Upside Repricing
Analysts have reduced their price target for Arcturus Therapeutics Holdings from US$42 to US$9, citing updated assumptions for the discount rate, revenue trends, and a lower forward P/E multiple, along with recent rating changes such as the downgrade to Neutral. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the move to a Neutral rating reinforcing the cut in the price target from US$42 to US$9.Aggiornamento narrativa • Dec 14
ARCT: Orphan mRNA Cystic Fibrosis Program Will Drive Future Upside
Analysts lowered their price target on Arcturus Therapeutics Holdings to 72 dollars from 128.81 dollars, reflecting a more cautious stance despite higher projected revenue growth and profit margins. They are reassessing valuation multiples and risk following recent rating actions.Articolo di analisi • Oct 28
The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shares have had a horrible month, losing 52% after a relatively...Articolo di analisi • Aug 29
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders have had their patience rewarded with a 32% share...Aggiornamento narrativa • Aug 15
Late-Stage Trials And Vaccine Partnerships Will Strengthen Market Potential
Analysts maintained an Overweight rating and reiterated a $47 price target for Arcturus Therapeutics Holdings, citing anticipated positive catalysts from the upcoming Phase 2 Cystic Fibrosis program readout in early Q3, while the consensus analyst price target remained unchanged at $70.89. Analyst Commentary Addition of an "upside 90-day catalyst watch" due to the upcoming Cystic Fibrosis program catalyst expected in early Q3.Articolo di analisi • Jul 31
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 04
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders are no doubt pleased to see that the share price has...
Nuova narrativa • Apr 26
KOSTAIVE Approval And Upcoming Vaccine Trials Will Open New Markets
European approval of the mRNA COVID-19 vaccine could significantly boost sales through broader market access in 31 countries.Articolo di analisi • Mar 20
Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders won't be pleased to see that the share price has had a...Articolo di analisi • Mar 09
Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) just released its latest yearly report and things are not looking...Seeking Alpha • Jan 28
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Summary Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating success beyond COVID-19 vaccines. ARCT-810 for OTCD (Phase 2 data 1H '25) must prove IV dosing every 2 weeks is worth better outcomes vs. current treatments; ammonia reduction key measure of success. ARCT-032 for CF (Phase 2 data 1H '25) targets a limited population ineligible for standard care; faces tough competition from Vertex's Trikafta (14% FEV1 improvement). Vaccine programs (COVID/flu) seem commercially challenged; late to market vs. Moderna/Pfizer with no clear differentiation in crowded space. $237M cash ($6.5M monthly burn) provides runway to 2027, but upcoming trial results in 1H '25 critical; downgrading to “sell” until clear differentiation emerges. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Summary Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025. CHMP opinion on KOSATIVE for Covid-19 expected December of 2025; Company has earned up to $462.1 million in milestone and upfront payments from CSL as of September 30th 2024. Read the full article on Seeking AlphaArticolo di analisi • Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders would be excited to see that the share price has had a...Articolo di analisi • Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 09
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Summary Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026. Read the full article on Seeking AlphaSeeking Alpha • Jun 08
Arcturus: A Hidden Gem In The Biotech Sector
Summary Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of the Kostaive vaccine and other programs are expected to drive revenue growth in the short and long term. Read the full article on Seeking AlphaArticolo di analisi • May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders are no doubt pleased to see that the share price has...Seeking Alpha • Apr 23
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Summary Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. and Europe. The therapy has the potential to generate significant revenues, similar to Vertex Pharmaceuticals' Trikafta treatment. ARCT's financial status is currently unstable, but the company has the potential to become profitable with the success of ARCT-032 and other therapies. Read the full article on Seeking AlphaArticolo di analisi • Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
With a price-to-sales (or "P/S") ratio of 3.2x Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) may be sending very...Seeking Alpha • Jan 31
Arcturus: H1 2024 Rare Disease Drug Data On Deck
Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 billion by 2030. Interim results from the phase 2 study, using ARCT-810 for the treatment of patients with OTC Deficiency, are expected in the 1st half of 2024. Received approval with partner CSL in Japan for ARCT-154 as the first self-amplifying mRNA vaccine for adults with COVID-19. Read the full article on Seeking AlphaArticolo di analisi • Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Key Insights Arcturus Therapeutics Holdings' estimated fair value is US$47.95 based on 2 Stage Free Cash Flow to Equity...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$93m |
| Mar 31 2026 | n/a | n/a | -US$79m |
| Dec 31 2025 | US$2m | US$750k | -US$66m |
| Sep 30 2025 | n/a | n/a | -US$67m |
| Jun 30 2025 | n/a | n/a | -US$60m |
| Mar 31 2025 | n/a | n/a | -US$68m |
| Dec 31 2024 | US$4m | US$695k | -US$81m |
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
Compensazione vs Mercato: La retribuzione totale di Joe ($USD 1.69M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.41M ).
Compensazione vs guadagni: La retribuzione di Joe è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Joe Payne (54 yo)
13.5yrs
Mandato
US$1,691,000
Compensazione
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 13.5yrs | US$1.69m | 5.21% $ 23.1m | |
| Founder | 13.7yrs | US$862.00k | 1.53% $ 6.8m | |
| Principal Accounting Officer & Controller | 2.5yrs | US$273.58k | 0.0077% $ 34.4k | |
| Chief Legal Officer | 6.1yrs | US$830.00k | 0% $ 0 | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President and Head of IR/PR & Marketing | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 3.1yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | 8yrs | Nessun dato | Nessun dato | |
| Chief Development Officer | 3.3yrs | Nessun dato | Nessun dato | |
| Chief Regulatory & Quality Assurance Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato |
3.2yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di ARCT è considerato esperto (durata media dell'incarico 3.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 13.5yrs | US$1.69m | 5.21% $ 23.1m | |
| Independent Director | 8.3yrs | US$221.50k | 0.34% $ 1.5m | |
| Member of the Vaccine Platform Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato | |
| Independent Director | 7yrs | US$224.00k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$234.00k | 0.035% $ 156.3k | |
| Independent Chairman of the Board | 2.3yrs | US$234.50k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$224.00k | 0.088% $ 389.8k | |
| Member of the Vaccine Platform Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 11.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 10.8yrs | Nessun dato | Nessun dato | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 4.5yrs | US$644.00k | Nessun dato | |
| Member of the Vaccine Platform Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato |
7.7yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ARCT sono considerati esperti (durata media dell'incarico 7.7 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/09 10:48 |
| Prezzo dell'azione a fine giornata | 2026/09/09 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Arcturus Therapeutics Holdings Inc. è coperta da 23 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Huidong Wang | Barclays |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |